PROJECT SYNDICATE
Prominent economists and climate policy officials express their concerns that the agreements and solutions adopted at the Glasgow COP26 summit will offer few tangible results. “If the threat of devastating global warming fails to jolt the world into meaningful collective action, it is difficult to see what will. But as the United Nations Climate Change Conference (COP26) in Glasgow gets down to the nitty-gritty, many fear that governments will once again pretend to support the climate cause while hoping that others will solve the crisis and pick up the tab.”
BUSINESSWEEK
-GlobalFoundries hopes to turn profitable amid the chip shortage. After years of losses, the newly public company shifted its focus to the low end of the market.
-Private equity funds are touting investments that can help the environment and society, but the impact is hard to measure.
SCIENCE
-A debate over whether the U.S. National Institutes of Health (NIH) funded unacceptably risky virus research in China has cast a spotlight on federal funding of what are known as gain-of-function (GOF) virology experiments. But ScienceInsider has learned that the only GOF experiments the United States approved and funded under a 2017 policy—two influenza studies that kicked off controversy over GOF research 10 years ago—have ended.
THE LANCET
-The Covid-19 pandemic has created an increased urgency to strengthen mental health systems in most countries. Mitigation strategies could incorporate ways to promote mental wellbeing and target determinants of poor mental health and interventions to treat those with a mental disorder. Taking no action to address the burden of major depressive disorder and anxiety disorders should not be an option.
BRITISH MEDICAL JOURNAL
-For researchers who were testing Pfizer’s vaccine at several sites in Texas during the fall of 2020 speed may have come at the cost of data integrity and patient safety. A regional director who was employed at the research organization Ventavia Research Group has told The BMJ that the company falsified data, un-blinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial.
JIM CRAMER’S MAD MONEY
- POSITIVE: Marvell Technology, Adobe, Coupang, Sea Limited, Bank of America, Khosla Ventures Acquisition II, iStar
- CAUTIOUS: Himax Technologies, The Container Store
SPECULATIVE: Matterport
TALKING POINTS MEMO
- Midway through Thursday’s hearing on whether former President Trump can block a subpoena issued by the House Jan. 6 Committee for records from his administration, U.S. District Judge Tanya Chutkan had a question: Why was the panel asking for records going all the way back to April 2020?
POLITICO
-As Speaker Nancy Pelosi furiously worked to unite her caucus around a centerpiece of the party’s domestic agenda, Sen. Joe Manchin is making it clear that he’s not paying much attention to what the House is crafting, memorably saying Wednesday that he has “no idea” what they are doing.
THE HILL
-Progressives are declaring victory ahead of a possible vote Thursday on President Biden’s social spending and climate package, while saying they shouldn’t be blamed for their party losing the governor’s race in Virginia.